ACKR2 and neoplasm: We next assessed tumor growth in both control and Ackr2-targeted B16-F10 cells, generated using shRNA, in immunodeficient NOD SCID gamma (NSG) mice, which lack T, B, and NK cells, and in immunocompetent C57BL/6 mice.